Helius Medical Technologies Inc. [HSDT] fell -93.06% so far this year. What now?
HELIOS Medical Technology Corporation [NASDAQ: HSDT] Its price declined by -0.08 points on Thursday, while share prices fell at $0.36 at the close of the session, down 17.68%. Company report on September 14, 2022 that HELIOS Medical Technologies, Inc. reports a stimulus grant under Nasdaq Listing Rule 5635(c)(4).
While finding safe stocks with the potential for huge gains isn’t always easy, we’ve found a few that can pay off well. In fact, within our report, Top 5 cheap stocks to own right nowIn this article, we have identified five stocks that we believe can increase in value even if you have $1,000 to invest.
Helios Medical Technologies, Inc. (Nasdaq: HSDT) (“Helios” or the “Company”), a neurotechnology company focused on neurological health, announced today that effective September 13, 2022, its Compensation Committee has approved a Helios Equity Award. Incentive Plan 2021, as a material inducement to an individual who enters into business with the company. The grants of equity are approved pursuant to Nasdaq’s Listing Rule 5635(c)(4), which also requires public announcement of stock awards that were not made under an approved shareholder’s equity plan.
In connection with entering into business with Helius, the individual, who was not a former employee or director of Helius, received an option to purchase 10,000 shares of the Company’s Class A common stock. The award value of the option is $0.54 per share, which is the closing price of Helios’ common stock on September 13, 2022, which is the date of the grant. The option is for ten years and runs over a period of four years, with 25% awarded on each of the first, second, third and fourth anniversaries of September 1, 2022, provided that the new employee continues to be employed on each such date, and is subject to acceleration or forfeiture upon occurrence of certain events as provided It is in the new tenant option agreement.
Helius Medical Technologies Inc.’s stock fell. It is now 93.06% down on its YTD trading value. HSDT stock saw an intraday high of $0.4239 and a low of $0.3516 per share. The company’s 52-week high is 15.05, which means that the current price is +2.39% higher than the all-time high touched on 01/04/22.
Compared to an average trading volume of 4.43 million shares, HSDT reached a trading volume of 3,229,991 on the last trading day, which is why market watchers consider the stock to be active.
What do top market experts say about Helios Medical Technologies, Inc.? [HSDT]?
Based on careful and fact-backed analysis by Wall Street experts, the current consensus on a target price for HSDT shares is $4.25 per share. Target price analysis and stock performance are usually carefully studied by market experts, and the current Wall Street consensus for HSDT stock is a set recommendation at 1.00. This rating represents a strong buy recommendation, on a scale of 1 to 5, where 5 means strong sell, 4 represents sell, 3 represents hold, and 2 indicates buy.
Noble Capital Markets has made an appreciation for the stock of Helios Medical Technologies, maintaining their opinion of the stock as Outperform, with their previous recommendation back on March 24, 2021.
The Average True Range (ATR) was determined by Helius Medical Technologies Inc. at 0.06, with a price-to-sales ratio for HSDT stock in the last twelve months of 14.67. The price-to-book ratio for the last quarter was 0.19, with the price-to-cash per share for the same quarter set at 0.22.
How has HSDT stock been performing lately?
HELIOS Medical Technology Corporation [HSDT] It fell into the red at the end of last week, fell in a negative direction and fell by -31.43. With this latest performance, HSDT shares are down -49.30% over the past four-week period, as well as -88.82% over the past six months — not to mention a -97.51% drop in the last year of trading.
Overbought and oversold stocks can be easily tracked by the Relative Strength Index (RSI), where an RSI result of over 70 is overbought, and any price below 30 indicates oversold conditions. The RSI of 50 represents neutral momentum in the market. The current RSI for the HSDT stock for the past two weeks was set at 31.44, with the RSI for the last one trading at 21.38, and the three-week RSI set at 35.71 for Helius Medical Technologies Inc. [HSDT]. The current moving average for the last 50 trading days for this stock is 0.6906 while it recorded at 0.4561 for the last trading week, and 2.6622 for the last 200 days.
HELIOS Medical Technology Corporation [HSDT]: A deeper look into the basics
Operating margin for any stock indicates how profitable the investment is, Helius Medical Technologies Inc. [HSDT] The stock currently has an operating margin of -3472.03 and a gross margin of +4.60. Helius Medical Technologies Inc.’s net profit margin was reported. Currently at -3473.56.
The return on equity for this stock fell to -239.73, with the return on assets remaining at -175.62.
The liquidity data of Helius Medical Technologies Inc. Interesting too, with the quick ratio at 3.40 and the current ratio at 3.60.
Business Insider Positions for Helius Medical Technologies Inc. [HSDT]
Currently, about $0 million, or 2.60% of HSDT’s stock, is in the hands of institutional investors. The three largest corporate owners of HSDT shares are: RENAISSANCE TECHNOLOGIES LLC with ownership of 46370, which is approximately 15.596% of the company’s market capitalization and about 0.10% of the total institutional ownership; ACT CAPITAL MANAGEMENT, LLC, which owns 35,263 shares of stock with an approximate value of $13000.0 in HSDT stock; and BOOTHBAY FUND MANAGEMENT, LLC, with $1,2000.0 in HSDT shares with ownership of approximately 0% of the company’s market value.
Positions increased in the shares of Helius Medical Technologies Inc. held by institutional investors at the end of August and at the time of the August report, as 7 institutional owners consolidated their position in Helius Medical Technologies Inc. [NASDAQ:HSDT] About 45,632 shares. In addition, 9 investors reduced their positions by 468,862 shares, while 9 investors held positions by 310,666 shares. The said changes put institutional holdings at 203,828 shares, according to the latest report from the Securities and Exchange Commission. HSDT stock had 3 new institutional investments totaling 32,882 shares, while 5 institutional investors sold deals totaling 447,843 shares during the same period.